• Investing Ideas
  • /
  • U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
462 companies
CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield

CDNA

CareDx
US$7.56-7.5%-8.9%US$391.4mUS$12.50PS1.4xE58.7%n/a

LYRA

Lyra Therapeutics
US$4.72-9.4%82.2%US$282.0mUS$12.00PS181xE12.6%n/a

CPRX

Catalyst Pharmaceuticals
US$14.89-1.4%-12.1%US$1.8bUS$26.71PE24.6xE18.2%n/a

ORXO.Y

Orexo
kr1.40-2.8%n/akr569.8mkr1.95PB9.7xE75.5%n/a

MKKG.Y

Merck KGaA
€32.252.7%-8.9%€66.0b€38.68PE23.4xE10.0%1.4%

SUWN

Sunwin Stevia International
US$0.00030%-96.4%US$59.9kn/aPB0.01xn/an/a

SGIO.Y

Shionogi
JP¥11.65-0.7%5.0%JP¥2.1tJP¥12.31PE13.4xE-0.6%2.1%

HRTX

Heron Therapeutics
US$2.45-5.4%0.8%US$368.4mUS$6.75PS2.9xE68.5%n/a

OPHL.F

Ono Pharmaceutical
JP¥14.47-9.3%-28.0%JP¥1.1tJP¥16.71PE8.5xE-6.9%3.5%

PBYI

Puma Biotechnology
US$5.02-2.9%90.2%US$242.2mUS$4.33PE11.2xE-53.5%n/a

MEOB.F

Mesoblast
AU$0.610.9%-0.8%AU$1.1bn/aPS92.9xE56.8%n/a

OXBD.F

Oxford Biomedica
UK£2.9111.1%n/aUK£228.5mUK£5.05PS1.9xE52.4%n/a

DHBU.F

Delivra Health Brands
CA$0.0251.8%58.7%CA$10.9mn/aPB2.9xE157.0%n/a

TRDA

Entrada Therapeutics
US$12.45-5.0%-2.4%US$403.5mUS$21.00PS3.1xE-1.5%n/a

PHBB.F

Pharmaron Beijing
CN¥2.250%n/aCN¥47.6bCN¥2.75PE33.7xE22.1%0.7%

CRPG.F

China Resources Pharmaceutical Group
HK$0.560%n/aHK$29.0bn/aPE7xE13.4%3.5%

ULIH.F

United Laboratories International Holdings
HK$0.890%n/aHK$15.5bHK$1.16PE6.6xE-0.7%3.9%

TGRN.F

Tong Ren Tang Technologies
HK$0.860%n/aHK$6.4bHK$1.29PE9.9xE7.1%3.9%

RGED.F

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Ft27.770%n/aFt1.7tFt35.23PE10.6xE17.0%4.6%

SHJB.F

Shanghai Junshi Biosciences
HK$1.860%n/aHK$24.9bHK$4.22PS6.5xE41.3%n/a

REGM.F

RemeGen
HK$2.090%-66.3%HK$27.2bHK$2.96PS12.2xE54.9%n/a

PROC

Procaps Group
US$2.730.6%-39.7%US$307.7mUS$4.75PE5.9xE-6.1%n/a

CSBR

Champions Oncology
US$5.02-0.8%3.3%US$68.2mUS$6.00PS1.4xS10.8%n/a

LADX

LadRx
US$2.3510.8%-71.6%US$1.2mn/aPE3.5xn/an/a
Page 8 of 20
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.